KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin: 2019-2025

Historic FCF Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -4.91%.

  • Esperion Therapeutics' FCF Margin rose 6380.00% to -4.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -30.71%, marking a year-over-year decrease of 2188.00%. This contributed to the annual value of -7.21% for FY2024, which is 10925.00% up from last year.
  • Esperion Therapeutics' FCF Margin amounted to -4.91% in Q3 2025, which was up 87.13% from -38.14% recorded in Q2 2025.
  • Esperion Therapeutics' 5-year FCF Margin high stood at 38.94% for Q1 2024, and its period low was -1,116.42% during Q1 2021.
  • Over the past 3 years, Esperion Therapeutics' median FCF Margin value was -50.57% (recorded in 2024), while the average stood at -59.92%.
  • Over the last 5 years, Esperion Therapeutics' FCF Margin had its largest YoY gain of 267,461bps in 2021, and its largest YoY loss of 18,323bps in 2021.
  • Over the past 5 years, Esperion Therapeutics' FCF Margin (Quarterly) stood at -374.69% in 2021, then soared by 14,899bps to -225.70% in 2022, then soared by 11,080bps to -114.90% in 2023, then surged by 6,433bps to -50.57% in 2024, then skyrocketed by 6,380bps to -4.91% in 2025.
  • Its FCF Margin was -4.91% in Q3 2025, compared to -38.14% in Q2 2025 and -34.81% in Q1 2025.